Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Other Accumulated Expenses (2017 - 2025)

Historic Other Accumulated Expenses for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $15.8 million.

  • Sutro Biopharma's Other Accumulated Expenses rose 35632.95% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 35632.95%. This contributed to the annual value of $4.0 million for FY2024, which is 333.59% up from last year.
  • According to the latest figures from Q3 2025, Sutro Biopharma's Other Accumulated Expenses is $15.8 million, which was up 35632.95% from $17.8 million recorded in Q2 2025.
  • In the past 5 years, Sutro Biopharma's Other Accumulated Expenses registered a high of $17.8 million during Q2 2025, and its lowest value of $185000.0 during Q1 2021.
  • Over the past 5 years, Sutro Biopharma's median Other Accumulated Expenses value was $3.5 million (recorded in 2024), while the average stood at $5.1 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 9139.03% in 2021, then soared by 140810.81% in 2022.
  • Over the past 5 years, Sutro Biopharma's Other Accumulated Expenses (Quarter) stood at $2.8 million in 2021, then increased by 12.0% to $3.1 million in 2022, then grew by 26.53% to $3.9 million in 2023, then rose by 3.34% to $4.0 million in 2024, then surged by 292.08% to $15.8 million in 2025.
  • Its Other Accumulated Expenses was $15.8 million in Q3 2025, compared to $17.8 million in Q2 2025 and $14.2 million in Q1 2025.